SLS - Company ID 0001390478
The table below shows SELLAS Life Sciences Group, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $71.79M | $13.89M | $2.53M | $17.13M | $21.36M | $35.30M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $75.21M |
| $16.33M |
| $3.17M |
| $17.76M |
| $23.04M |
| $36.92M |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M |
| Total assets | $78.34M | $19.43M | $6.22M | $20.94M | $26.27M | $46.05M |
| Accounts payable | $2.95M | $3.50M | $5.64M | $3.36M | $2.14M | $4.66M |
| Total current liabilities | $7.02M | $9.51M | $13.73M | $15.52M | $4.98M | $12.34M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $7.47M | $9.97M | $14.20M | $16.09M | $5.93M | $18.09M |
| Retained earnings | -$274.99M | -$248.13M | -$217.24M | -$179.90M | -$138.60M | -$117.90M |
| Total equity | $70.87M | $9.46M | -$7.98M | $4.85M | $20.35M | $27.96M |